Stockchase Opinions

Stephen Takacsy, B. Eng, MBAVelan IncVLN.TOPAST TOP PICKOct 31, 2019

(A Top Pick Dec 03/18, Down 21%) It is down on a failing of them to buy back their stock and support it. He became activist with several other shareholders and they have now made some tough decisions about closing money losing plants and dropping unprofitable business lines. The latest results were a significant improvement in gross margins. They announced they re-instituted the share buyback program. It is a screaming buy.
$6.90

Stock price when the opinion was issued

$15.75

As of Jun 05, 2026. Market Open.

INDUSTRIAL PRODUCTS
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

WATCH

Bought in just before the takeout deal was nixed by the French government. Rocket ride lately on the nuclear bid hype, so he sold. De facto world gold standard in nuclear valves. Cheap vs. tangible book value. May buy again if cheap enough. Sees eventual takeover.

PAST TOP PICK
(A Top Pick Sep 25/23, Down 37%)

They remain the leader in nuclear valves. Shockingly, the French government blocked an American company from buying this small Montreal company. So, the family decided to sell the company and he expects it will be at a higher price. Their backlog and margins are growing. He still owns it. Trades below tangible book value.

HOLD

Chart looks the way it does because acquisition of its very lucrative nuclear valve business by an American buyer was blocked by the French government. Illiquid stock. The family still wants to sell. Deep value, good return if patient.

TOP PICK

It makes high quality valves for the nuclear industry. It had a take-over offer of $13 a share and he sold at around $12.50. However there were worries that the French Government might block the sale so the stock price dropped. The nuclear valves division is based in France. However he feels that the deal will go through in the next few months at $13.00 so has been buying it back as a short-term investment with up to 30% upside.
Buy 1  Hold 0  Sell 0 

(Analysts’ price target is $5.37)
HOLD

At this late stage, there won't be another offer, so you'll have to be happy with $13. Should have received a much higher price. Asbestos litigation costs did them in.

Unspecified

The litigation costs over asbestos content have been increasing and eating into profits. It is a jewel of a company and should be worth more than the present offer. There is the possibility of a higher offer.

PAST TOP PICK
(A Top Pick Jan 20/22, Down 39%)

Lead in their business. Just completed a successful turnaround and enjoying strong sales and a record backlog. Cheap, trading at under a third of book value. Expects a strong next quarter, and that's when the company should sell itself. He's pushing for a sale.

PAST TOP PICK
(A Top Pick Jan 20/22, Down 42%) It is a world leader in the design and manufacture of complex industrial valves and is the gold standard for nuclear valves. It has completed a successful turnaround plan and has a record backlog of of high margin business. Trading at less than 1/3 of book value, it is one of the cheapest value stocks. No analysts cover it. He and several other institutional investors are pushing for the sale or privatization of the company to unlock shareholder value. The stock is worth much more than $5, maybe even $20.
Unspecified
It is a valve maker where the end markets have great importance, especially energy and nuclear. Has a strong backlog. He is one of the activists pushing hard for the company to sell to a strategic partner for better profitability. Has a new CEO who is doing very well. Trading well below liquidation value.
BUY
Business has had strong financial results the past few quarters. Significantly increased gross margins. Turnaround plan is working as hoped. Very under valued company. Happy with improvements in corporate governance. Industrial valve backlog in orders. Expecting share buybacks to start soon (next year). Believes company is worth over $20 a share.
BUY
A leader in nuclear valves. Four years ago he was activist shareholder, but the company has made great strides since then. Their turnaround plan is in full swing. Gross margins have increased a lot and they have a record backlog. Are benefitting from energy infrastructure spending and the need for more energy. Company remains way below book value, so it's cheap. It could be sold one day. A long-term hold for a deep value investor.
TOP PICK
One of the cheapest stocks on TSX. Recent financial results were excellent with improved margins. Strong demand for nuclear energy. Trading at 50% of "net-book value". Expects company to start buying back shares. Believes value of shares to be ~$20.
TOP PICK
Fantastic results a few days ago. Hugely improved profit margins. Healthy backlog that should grow, since its big markets are energy and nuclear, which are hot right now. Trades at less than 50% of book value. His firm is pushing for a strategic sale, looking for $20-30 per share. No dividend.
BUY
They were a strong activist shareholder a few years ago and now hold a seat on the board. The transformation is nearly complete and recent earnings proved it is working, with a record order backlog and expanding margins. They expect solid earnings when reported in January. At some point it could be an acquisition target, where he thinks it would fetch 3x its current value. You have to be patient. Very little downside.
HOLD
World leaders in nuclear valves. Has become more shareholder friendly, focusing on higher margins and more profitable areas. Record backlogs, so this year should be very strong. Nominated first non-family chairman ever, a positive. Significantly below tangible book value. His firm is pushing to unlock shareholder value. Support at these levels and should go higher.